Global Drug Facility Annual Report 2011 [.pdf] - Stop TB Partnership

14
GLOBAL DRUG
FACILITY
Diagnostics/ new diagnostics
Expenditure on diagnostics/ new diagnostics for the Expand-TB Project funded by UNITAID
increased by 52% between 2010 and 2011. The main reason for this increase is that the
project, which was launched in 2009, was scaled up rapidly throughout 2011. By this time,
challenges initially experienced in establishing laboratories and improving infrastructure
had been addressed.
2008 $ 126 232
2009 $ 272 743
2010 $ 3 077 276
2011 $ 6 404 731
Figure 8 Value of diagnostics / new diagnostics procured by year (UNITAID funded)
Supplemental costs
Freight, procurement agents, quality control, insurance, pre-shipment inspection.
The level of expenditure on supplemental costs associated with order placement remained
relatively constant from 2010 to 2011. The major change was increased freight costs, due to
increased quantities of drugs and diagnostics procured. Quality control costs were reduced
significantly after February 2011, at which time a new policy was put in place: to cease 100%
batch testing and instead to conduct randomised batch testing of 10% of all prequalified
products and 20% of all Expert Review Panel (ERP) products. 1
1
For further explanation of the ERP, refer to Quality assurance section on page 16.